Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Douglas Pharmaceuticals Secures US licensing Deal to Treat High Grade Cervical Dysplasia
Details : Under the license agreement with Douglas, Dare will be responsible for advancing the development of R-131-2 (Lopinavir/Ritonavir) in the U.S. for the treatment for cervical intraepithelial neoplasia.
Brand Name : R-131-2
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : FB-101
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Sofinnova Partners
Deal Size : $38.0 million
Deal Type : Series A Financing
Women’s Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment
Details : Freya will advance the development of its lead drug, FB-101, an investigational vaginal microbial immunotherapeutic, for infertility in women with dysbiotic vaginal microbiota.
Brand Name : FB-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 19, 2024
Lead Product(s) : FB-101
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Sofinnova Partners
Deal Size : $38.0 million
Deal Type : Series A Financing
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : ARPA-H
Deal Size : $10.0 million
Deal Type : Funding
Daré Bioscience Wins $10M Award from ARPA-H for Women’s Health
Details : The funding will be used to advance DARE-HPV, a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease.
Brand Name : DARE-HPV
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : ARPA-H
Deal Size : $10.0 million
Deal Type : Funding
Lead Product(s) : Cannabinoid-based Drug
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gynica Launches First-In-Human Trial Of IntraVag© Treatment for Endometriosis
Details : IntraVag technology allows controlled API release to target organs, evaluated with cannabinoid-based drug candidates S-301 and S-302 for endometriosis-associated pain treatment.
Brand Name : S-301
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 14, 2024
Lead Product(s) : Cannabinoid-based Drug
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CBP-4888
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Google Ventures
Deal Size : $75.0 million
Deal Type : Series B Financing
Comanche Biopharma Closes $75 Million Series B Financing for Preeclampsia Treatment
Details : Comanche will initiate a clinical study of CBP-4888, a fixed-dose combination of two siRNA oligonucleotides targeting soluble fms-like tyrosine kinase–1 (sFLT1) in preeclamptic patients.
Brand Name : CBP-4888
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 17, 2024
Lead Product(s) : CBP-4888
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Google Ventures
Deal Size : $75.0 million
Deal Type : Series B Financing
Lead Product(s) : Diclofenac
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DARE-PDM1 (diclofenac) is a vaginal hydrogel which inhibits Cox-1 and Cox-2. It is being evaluated in phase 1 clinical trials for the treatment of primary dysmenorrhea.
Brand Name : DARE-PDM1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2023
Lead Product(s) : Diclofenac
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : FB101
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Sofinnova Partners
Deal Size : $38.0 million
Deal Type : Series A Financing
Details : Freya will advance the clinical development of its lead drug candidate, FB101, an investigational vaginal microbial immunotherapeutic, for the treatment of infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive te...
Brand Name : FB101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 12, 2023
Lead Product(s) : FB101
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Sofinnova Partners
Deal Size : $38.0 million
Deal Type : Series A Financing
Lead Product(s) : siRNA-2283,siRNA-2519
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CBP-4888 is a fixed-dose combination of siRNA-2283 and siRNA-2519 targeting two soluble fms-like tyrosine kinase–1 (sFLT1) mRNA isoforms, which is investigated for the treatment of sFlt-1 mediated pre-term preeclampsia.
Brand Name : CBP-4888
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 23, 2023
Lead Product(s) : siRNA-2283,siRNA-2519
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sildenafil citrate cream is applied locally to the vaginal tissue prior to sexual activity to facilitate vasodilation and increase blood flow directly to the genital tissue to improve the physical arousal responsein womens with FSAD.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 20, 2023
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DARE-PDM1 is a novel delivery of the diclofenac sodium, a NSAID drug which inhibits COX-1 and COX-2 responsible for producing PGs which contributes in inflammation and pain signalling. It uses Daré’s proprietary hydrogel technology targeted at treatin...
Brand Name : DARE-PDM1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2023
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?